Q1 EPS Forecast for Allurion Technologies Cut by Analyst

Allurion Technologies Inc. (NYSE:ALUR) – Equities research analysts at Roth Capital dropped their Q1 2025 earnings per share estimates for shares of Allurion Technologies in a research report issued on Wednesday, March 5th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of ($22.91) for the quarter, down from their prior forecast of ($3.25). The consensus estimate for Allurion Technologies’ current full-year earnings is ($9.96) per share. Roth Capital also issued estimates for Allurion Technologies’ Q2 2025 earnings at ($17.35) EPS, Q3 2025 earnings at ($14.19) EPS, Q4 2025 earnings at ($3.61) EPS, FY2025 earnings at ($58.06) EPS and FY2026 earnings at ($4.41) EPS.

Separately, Chardan Capital lowered shares of Allurion Technologies from a “buy” rating to a “neutral” rating in a research report on Thursday, November 14th.

Allurion Technologies Trading Down 4.3 %

Shares of Allurion Technologies stock opened at $2.45 on Monday. Allurion Technologies has a 1 year low of $2.37 and a 1 year high of $98.75. The company’s fifty day simple moving average is $5.23 and its 200-day simple moving average is $11.07. The company has a market cap of $11.75 million, a price-to-earnings ratio of -0.20 and a beta of -0.59.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC boosted its stake in Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,330 shares of the company’s stock after buying an additional 149,484 shares during the quarter. Geode Capital Management LLC owned approximately 0.80% of Allurion Technologies worth $317,000 at the end of the most recent quarter. 21.39% of the stock is currently owned by institutional investors.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.